Literature DB >> 21406458

Early clinical response to treatment predicts 5-year outcome in RA patients: follow-up results from the CAMERA study.

M F Bakker1, J W G Jacobs, P M J Welsing, S A Vreugdenhil, C van Booma-Frankfort, S P Linn-Rasker, E Ton, F P J G Lafeber, J W J Bijlsma.   

Abstract

OBJECTIVE: To investigate the long-term effects of the tight control (TC) and conventional (CT) methotrexate-based strategies of the Computer Assisted Management in Early Rheumatoid Arthritis trial in early rheumatoid arthritis and evaluate the predictive value of an early response to treatment.
METHODS: Clinical and radiographic 5-year outcome was compared between initial strategies. Patients were classified according to the EULAR response criteria. The prognostic value of early response to treatment in addition to established predictors was analysed by multiple linear regression analyses.
RESULTS: 5 years of data were available for 205 of 299 patients, with no indication for selective drop-out. At 5 years there was no longer any significant difference for clinical and radiographic outcomes between treatment strategies applied during the first 2 years. Good-responders had a mean disease activity score of 2.39 (1.2) and median yearly radiographic progression rate of 0.6 (0.0 to 2.2) at 5 years; significantly lower (both p<0.02) when compared to moderate- and non-responders. Multiple regression analysis showed that early response to treatment is an independent predictor of 5-year outcome, irrespective of treatment strategy.
CONCLUSIONS: The difference in disease activity between treatment strategies disappeared over the years. Good-response to treatment independently predicts significantly better 5-year clinical and radiographic outcome. The TC principle probably should be continued in the long-term.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21406458     DOI: 10.1136/ard.2010.137943

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  13 in total

1.  [German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm].

Authors:  K Krüger; J Wollenhaupt; K Albrecht; R Alten; M Backhaus; C Baerwald; W Bolten; J Braun; H Burkhardt; G Burmester; M Gaubitz; A Gause; E Gromnica-Ihle; H Kellner; J Kuipers; A Krause; H-M Lorenz; B Manger; H Nüßlein; H-G Pott; A Rubbert-Roth; M Schneider; C Specker; H Schulze-Koops; H-P Tony; S Wassenberg; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2012-09       Impact factor: 1.372

2.  Long-term clinical, functional, and cost outcomes for early rheumatoid arthritis patients who did or did not achieve early remission in a real-world treat-to-target strategy.

Authors:  Peter M Ten Klooster; Martijn A H Oude Voshaar; Walid Fakhouri; Inmaculada de la Torre; Claudia Nicolay; Mart A F J van de Laar
Journal:  Clin Rheumatol       Date:  2019-06-03       Impact factor: 2.980

Review 3.  [Systematic literature research for S1 guidelines on sequential medical treatment of rheumatoid arthritis].

Authors:  K Albrecht; K Krüger; U Müller-Ladner; J Wollenhaupt
Journal:  Z Rheumatol       Date:  2012-09       Impact factor: 1.372

4.  Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA: results from the TEAR Trial.

Authors:  Jeffrey R Curtis; Theresa McVie; Ted R Mikuls; Richard J Reynolds; Iris Navarro-Millán; James O'Dell; Larry W Moreland; S Louis Bridges; Veena K Ranganath; Stacey S Cofield
Journal:  J Rheumatol       Date:  2013-04-15       Impact factor: 4.666

5.  A profile of immune response to herpesvirus is associated with radiographic joint damage in rheumatoid arthritis.

Authors:  John M Davis; Keith L Knutson; John A Skinner; Michael A Strausbauch; Cynthia S Crowson; Terry M Therneau; Peter J Wettstein; Eric L Matteson; Sherine E Gabriel
Journal:  Arthritis Res Ther       Date:  2012-01-31       Impact factor: 5.156

6.  Trajectory of intensive treat-to-target disease modifying drug regimen in an observational study of an early rheumatoid arthritis cohort.

Authors:  Douglas White; Helen Pahau; Emily Duggan; Sanjoy Paul; Ranjeny Thomas
Journal:  BMJ Open       Date:  2013-07-31       Impact factor: 2.692

7.  Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study.

Authors:  Arthur Kavanaugh; Roy M Fleischmann; Paul Emery; Hartmut Kupper; Laura Redden; Benoit Guerette; Sourav Santra; Josef S Smolen
Journal:  Ann Rheum Dis       Date:  2012-05-05       Impact factor: 19.103

Review 8.  Rheumatoid arthritis treatment: the earlier the better to prevent joint damage.

Authors:  Sara Monti; Carlomaurizio Montecucco; Serena Bugatti; Roberto Caporali
Journal:  RMD Open       Date:  2015-08-15

9.  Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis.

Authors:  Claudio Carini; Ewan Hunter; Aroul S Ramadass; Jayne Green; Alexandre Akoulitchev; Iain B McInnes; Carl S Goodyear
Journal:  J Transl Med       Date:  2018-01-29       Impact factor: 5.531

10.  Can baseline ultrasound results help to predict failure to achieve DAS28 remission after 1 year of tight control treatment in early RA patients?

Authors:  D F Ten Cate; J W G Jacobs; W A A Swen; J M W Hazes; M H de Jager; N M Basoski; C J Haagsma; J J Luime; A H Gerards
Journal:  Arthritis Res Ther       Date:  2018-01-30       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.